Trastuzumab with FLOT Regimen for the Perioperative Treatment of Resectable HER2 + Advanced Gastric Cancer: A Retrospective Study

Gangling Tong; Shuluan Li; Lin Lin; Lirui He; Li Wang; Guoqing Lv; Ruinian Zheng; Shubin Wang

doi:10.2147/CMAR.S239420

Trastuzumab with FLOT Regimen for the Perioperative Treatment of Resectable HER2 + Advanced Gastric Cancer: A Retrospective Study

Cancer Manag Res. 2020 Apr 8:12:2481-2489. doi: 10.2147/CMAR.S239420. eCollection 2020.

Authors

Gangling Tong^#¹, Shuluan Li^#², Lin Lin^#³, Lirui He¹, Li Wang¹, Guoqing Lv¹, Ruinian Zheng⁴, Shubin Wang¹

Affiliations

¹ Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, People's Republic of China.
² National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong 518116, People's Republic of China.
³ Department of Oncology, Shenzhen Second People's Hospital, Shenzhen, Guangdong 518036, People's Republic of China.
⁴ Department of Oncology, Affiliated Dongguan People's Hospital, Southern Medical University, Dongguan, Guangdong 523000, People's Republic of China.

^# Contributed equally.

Abstract

Background: The aim of this study was to evaluate the efficacy and safety of trastuzumab, combined with the FLOT regimen, in the perioperative treatment of resectable HER-2-positive advanced gastric cancer.

Methods: Overall, 45 patients were divided into two groups; 29 patients in the experimental group were treated with trastuzumab combined with FLOT and 16 patients in the control group were treated with FLOT alone. The primary endpoint was objective response rate (ORR), and the secondary endpoints were disease control rate (DCR), tumor regression grade (TRG), surgical margin, side effects, and overall survival.

Results: In the experimental and control groups, ORR was 72.4% and 43.8% (p=0.226), DCR was 89.7% and 87.5%, R0 resection rate was 96.5% and 93.7%, total/subtotal tumor regression grade was 17.2% and 6.3%, partial tumor regression grade was 27.6% and 18.7% (p=0.468), and 2-year survival rate was 78.1% and 73.9% (p=0.932), respectively. The common side effects were agranulocytosis and vomiting. There was no significant difference between the two groups.

Conclusion: Trastuzumab combined with FLOT has a good curative effect and safety profile in the perioperative treatment of patients with resectable HER-2-positive advanced gastric cancer. In addition, trastuzumab + FLOT had the same result as FLOT alone, as there was no significant benefit with the addition of T in the group studied.

Keywords: HER2; gastric cancer; perioperative chemotherapy; trastuzumab.

Grants and funding

This work was supported by Natural Science Foundation of Guangdong Province (No. 2018A0303100026); Shenzhen Science and Technology Innovation Committee Fund (GJHZ20180420180754917) and Sanming Project of Shenzhen (SZSM201612041).